Cargando…
Asenapine Treatment in Pediatric Patients with Bipolar I Disorder or Schizophrenia: A Review
Asenapine, administered as a twice-daily (BID) sublingual tablet, is approved in the US as monotherapy for the acute treatment of manic and mixed episodes of bipolar I disorder in children and adolescents aged 10–17 years based on the positive results of one 3-week, double-blind, placebo-controlled...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856894/ https://www.ncbi.nlm.nih.gov/pubmed/29170943 http://dx.doi.org/10.1007/s40272-017-0274-9 |